Smith & Nephew plc (LON:SN)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 11.66B |
| Revenue (ttm) | 4.58B |
| Net Income (ttm) | 464.38M |
| Shares Out | 849.81M |
| EPS (ttm) | 0.53 |
| PE Ratio | 25.78 |
| Forward PE | 16.33 |
| Dividend | 0.28 (2.06%) |
| Ex-Dividend Date | Oct 2, 2025 |
| Volume | 5,287,194 |
| Average Volume | 2,508,738 |
| Open | 1,375.50 |
| Previous Close | 1,371.50 |
| Day's Range | 1,289.50 - 1,375.50 |
| 52-Week Range | 937.80 - 1,441.50 |
| Beta | 0.65 |
| RSI | 52.51 |
| Earnings Date | Mar 2, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsNews
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase it...
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2025 Earnings Call March 2, 2026 3:30 AM ESTCompany ParticipantsDeepak Nath - CEO & DirectorJohn Rogers - CFO &...
Smith & Nephew PLC (SNN) Stock Price Down 4.72% on Mar 2
Smith & Nephew PLC (SNN) Stock Price Down 4.72% on Mar 2
Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report
Smith+Nephew (NYSE: SNN) reported revenue growth across its operating segments for the fourth quarter of fiscal 2025. The medical technology... The post Earnings Summary: A snapshot of Smith+Nephew’s ...
Smith & Nephew plc 2025 Q4 - Results - Earnings Call Presentation
2026-03-02. The following slide deck was published by Smith & Nephew plc in conjunction with their 2025 Q4 earnings call.
Smith & Nephew (SNN) Exceeds Q4 Revenue Expectations with Strong Growth
Smith & Nephew (SNN) Exceeds Q4 Revenue Expectations with Strong Growth
Smith & Nephew FY25 Results Rise, Lifts Dividend; Sees Growth Ahead
(RTTNews) - Smith & Nephew Plc (SNN, SN.L), a British medical technology company, reported Monday significantly higher profit in fiscal 2025, with increased revenues. Further, the company lifted divid...
Smith & Nephew reports Q4 results; introduces FY26 and FY28 outlook
Smith & Nephew press release (SNN): Q4 Revenue of $1.7B (+8.3% Y/Y) beats by $20M. Orthopaedics delivered underlying revenue growth of 7.9% (reported growth 9.8
UK Stock Market News: Bunzl, Smith & Nephew, Sage
Bunzl posts weak numbers, but marginally better than expected, strong margin growth at S+N, Sage announces £300m share buyback
UK medical products maker Smith & Nephew's annual profit jumps 15.5%
British medical products maker Smith & Nephew posted a 15.5% jump in annual profit on Monday, building on the success of its turnaround plans, which delivered cost savings and boosted growth across it...
Smith+Nephew Expands Portfolio with New U.S. Distribution Deal
Smith+Nephew Expands Portfolio with New U.S. Distribution Deal
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A'TOMIC™ Nitinol Fixation System ...
SI-BONE outlines 14%-16% revenue growth for 2026 with new product launches and Smith & Nephew partnership
Smith & Nephew (SNN) Strengthens Portfolio with SI-Bone Agreement
Smith & Nephew (SNN) Strengthens Portfolio with SI-Bone Agreement
Smith+Nephew signs distribution agreement with SI-BONE
Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the globa...
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder r...
UK's Smith & Nephew to buy Integrity Orthopaedics for up to $450 million
British medical products maker Smith & Nephew will buy U.S.-based Integrity Orthopaedics in a deal that could be valued at up to $450 million, the company said on Monday.
Smith & Nephew: Improving And Undervalued, But Mind The Knees
Smith & Nephew has outperformed peers, driven by strong sports medicine and wound care, despite ongoing ortho business challenges. SNN's major joints segment remains a sore spot, with ongoing underper...
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew boosts 2025 cashflow forecast and unveils medium-term targets
British medical products maker Smith & Nephew raised its 2025 free cash flow forecast to around $800 million and unveiled new medium-term targets ahead of its Capital Markets Day Event on Monday.
Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript
Smith & Nephew plc ( SNN) Q3 2025 Sales Call November 6, 2025 3:30 AM EST Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Re...
Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release
Smith & Nephew plc maintains a 'Hold' rating due to valuation concerns and limited near-term upside despite recent operational improvements. Sequential growth across all business units and a 100 basis...
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound thera...
UFC® and Smith+Nephew announce multi-year extension of partnership
Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts or...
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound ...